Medicare Negotiates New Pricing for Part D Medications, Impact on Drug Costs

Medicare is set to introduce negotiated prices for 15 additional Part D medications, promising significant savings for beneficiaries by 2027.

Starting January 1, Medicare will implement new negotiated pricing for drugs including Ozempic, Wegovy, Trelegy, and Xtandi. The Centers for Medicare & Medicaid Services (CMS) projects these changes to save beneficiaries approximately $685 million by 2027. This reflects an ongoing effort by Medicare to balance costs and access, placing pressure on pharmaceutical companies to participate in negotiations to maintain drug affordability. The recent legal victory by AbbVie to exclude Botox from these negotiations indicates potential pushback from drug manufacturers, although further appeals could alter the outcome.

Medicaid Rebates and Purchasing Pools

State-level Medicaid supplemental rebates have been on the rise, showing marked growth from $19 per beneficiary in 2017 to $93 by 2024. This shift represents an uptick from 2% to 7% of total Medicaid drug expenses. States engaging in multistate purchasing pools have achieved significantly better outcomes, saving around $20 more per Medicaid beneficiary compared to solitary state negotiations. These strategies are increasingly vital as states grapple with controlling healthcare costs while maintaining robust access to essential medications.

Restructuring at CVS Health

CVS Health has announced plans to reorganize its business structure by mid-2028. The company will split into two distinct entities: one focusing on managing Aetna, the Caremark pharmacy benefit manager (PBM), Oak Street Health, and its specialized pharmaceutical services, and the other on its roughly 9,000 retail outlets. According to CVS Health CEO David Joyner, this strategic division aims to optimize operations and was not influenced by regulatory pressure, despite legislative efforts to limit PBM ownership of pharmacies.

Federal Regulatory Developments

Federal oversight continues to impact the health insurance landscape as two entities were recently denied recertification under the No Surprises Act's independent dispute resolution process due to unmet performance standards. With ongoing reviews of additional organizations, these moves signal a push for greater accountability and quality in dispute resolutions. Moreover, proposed adjustments to the CMS star-rating measures return potential reductions in Medicare Advantage bonus payments, influencing plans covering millions of enrollees.

Innovations in AI-Driven Healthcare

Healthcare innovation is gaining momentum with advancements in AI technologies. Notably, a Stony Brook University study found that physicians favored AI-generated discharge summaries in 95% of cases. Similarly, Penn Medicine's Percival AI model demonstrated proficiency in identifying conditions on CT scans beyond original targets. Legislative efforts are also underway to integrate AI into healthcare through Medicare, with Senate HELP Chair Bill Cassidy seeking feedback on draft proposals by December 1, potentially paving the way for AI-driven diagnostic and procedural advances.

These developments highlight the evolving landscape of drug pricing, insurance restructuring, and the integration of AI in healthcare. Industry stakeholders must remain vigilant to adapt to these changes, which will undoubtedly influence coverage options, cost management, and the regulatory environment in the coming years.